Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2005

Open Access 01-12-2005 | Research

Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis

Authors: Maria De Santis, Silvia Bosello, Giuseppe La Torre, Anna Capuano, Barbara Tolusso, Gabriella Pagliari, Riccardo Pistelli, Francesco Maria Danza, Angelo Zoli, Gianfranco Ferraccioli

Published in: Respiratory Research | Issue 1/2005

Login to get access

Abstract

Background

A progressive lung disease and a worse survival have been observed in patients with systemic sclerosis and alveolitis. The objective of this study was to define the functional, radiological and biological markers of alveolitis in SSc patients.

Methods

100 SSc patients (76 with limited and 24 with diffuse disease) underwent a multistep assessment of cardiopulmonary system: pulmonary function tests (PFTs) every 6–12 months, echocardiography, high resolution computed tomography (HRCT) and bronchoalveolar lavage (BAL), if clinically advisable. Alveolar and interstitial scores on HRCT and IL-6 plasma levels were also assessed as lung disease activity indices.

Results

90 SSc patients with abnormal PFTs and 3 with signs and/or symptoms of lung involvement and normal PFTs underwent HRCT and echocardiography. HRCT revealed evidence of fibrosis in 87 (93.5%) patients, with 55 (59.1%) showing both ground glass attenuation and fibrosis. In 42 patients who had exhibited ground glass on HRCT and consented to undergo BAL, 16 (38.1%) revealed alveolitis. 12 (75%) of these patients had restrictive lung disease (p < 0.0001) and presented diffuse skin involvement (p = 0.0009). IL-6 plasma levels were higher in patients with alveolitis than in patients without (p = 0.041). On logistic regression model the best independent predictors of alveolitis were diffuse skin involvement (OR(95%CIs):12.80(2.54–64.37)) and skin score > 14 (OR(95%CIs):7.03(1.40–34.33)). The alveolar score showed a significant correlation with IL-6 plasma levels (r = 0.36, p = 0.001) and with the skin score (r = 0.33, p = 0.001). Cultures of BAL fluid resulted positive in 10 (23.8%) of the 42 patients that underwent BAL and after one year a deterioration in PFTs occurred in 8 (80%) of these patients (p = 0.01). Pulmonary artery systolic pressure ≥ 40 mmHg was found in 6 (37.5%) patients with alveolitis.

Conclusion

We found alveolitis only in 38.1% of the patients who had exhibited ground glass on HRCT and then underwent BAL, probably because the concomitant fibrosis influenced results. A diffuse skin involvement and a restrictive pattern on PFTs together with ground glass on HRCT were judged possible markers of alveolitis, a BAL examination being indicated as the next step. Nevertheless BAL would be necessary to detect any infections of the lower respiratory tract that may cause further deterioration in lung function.
Appendix
Available only for authorised users
Literature
1.
2.
Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM: Histopathologic subset of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581–86.CrossRefPubMed
3.
Morgan C, Knight C, Lunt M, Black CM, Silman AJ: Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003, 62:146–50.CrossRefPubMedPubMedCentral
4.
White B, Moore WC, Wigley FM, Xiao HQ, Wise RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947–54.CrossRefPubMed
5.
Klech H, Pohl W: Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group on BAL. Eur Respir J 1989, 2:561–85.
6.
Baker AM, Bowton DL, Haponik EF: Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantitative bronchoscopic cultures. Chest 1995, 107:85–95.CrossRefPubMed
7.
Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581–90.CrossRef
8.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F: Classification, subset and pathogenesis. J Rheumatol 1988, 15:202–5.PubMed
9.
Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003, 62:904–5.CrossRefPubMedPubMedCentral
10.
Reveille JD, Solomon DH, ACR ad hoc committee on immunologic testing guidelines: Evidence-based guidelines fort he use of immunologic tests: anticentromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 2003, 49:399–412.CrossRefPubMed
11.
American Thoracic Society: Standardization of Spirometry-1994 Update. Am J Respir Crit Care Med 1995, 152:1107–36.CrossRef
12.
American Thoracic Society: Single breath Carbon Monoxide Diffusing Capacity (Transfer Factor). Recommendation for a standard technique-1995 Update. Am J Respir Crit Care Med 1995, 152:2185–98.CrossRef
13.
Paoletti P, Viegi G, Pistelli G, Di Pede F, Fazzi P, Polato R, Saetta M, Zambon R, Carli G, Giuntini C: Reference equations for the single breath diffusing capacity: a cross sectional analysis and effect of body size and age. Am Rev Respir Dis 1985, 132:806–13.PubMed
14.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Vernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993, (Suppl 16):5–40.
15.
Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W: Assessment of disease severity and prognosis in SSc. Clin Exp Rheumatol 2003, 21:S42–6.PubMed
16.
Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP 3rd, Toews G: Thin-section CT obtained at 10 mm increments versus three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997, 169:977–83.CrossRefPubMed
17.
McQuillan BM, Picard MH, Leavitt M, Weyman AE: Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001, 104:2797–2802.CrossRefPubMed
18.
The Joint statement of the ATS and ETS: Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med 2000, 161:646–64.CrossRef
19.
Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, Fruhmann G: Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996, 154:400–6.CrossRefPubMed
20.
Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A: Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999, 58:635–40.CrossRefPubMedPubMedCentral
21.
Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, Roth MD: Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004, 50:1909–17.CrossRefPubMed
22.
Silver RM, Scott Miller K, Kinsella MB, Smith EA, Schabel SI: Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990, 88:470–6.CrossRefPubMed
23.
Muller NL, Staples CA, Miller RR, Vedal S, Thurlbeck WM, Ostrow DN: Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radiology 1987, 165:731–4.CrossRefPubMed
24.
Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, du Bois RM: High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992, 47:738–42.CrossRefPubMedPubMedCentral
25.
Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron PY: Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function test and bronchoalveolar lavage. Radiology 1993, 188:499–506.CrossRefPubMed
26.
Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Hoier-madsen M, Wiik A, Petersen J: Clinical features and serum antinuclear antibodies in 230 danish patients with systemic sclerosis. Br J Rheumatol 1998, 37:39–45.CrossRefPubMed
27.
Della Rossa A, Valentini G, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, Matucci Cerinic M, Belch JF, Black CM, Becvar R, Bruhlman P, Cozzi F, Czirjak l, Drosos AA, Dziankowska B, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Scorza R, Tirri E, van der Hoogen FHJ, Vlachoyiannopoulos PG: European multicentre study to define disease activity criteria for systemic sclerosis. I Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001, 60:585–91.CrossRefPubMed
28.
Steen VD, Conte C, Owens GR, Medsger TA Jr: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283–9.CrossRefPubMed
29.
Ooi GC, Mok MY, Tsang WT, Wong Y, Khong PL, Fung PCW, Chan S, Tse HF, Wong RWS, Lam WK, Lau CS: Interstitial lung disease in systemic sclerosis. An HRCT-clinical correlative study. Acta Rad 2003, 44:258–64.
30.
Chang B, Wigley FM, White B, Wise RA: Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003, 30:2398–405.PubMed
31.
Desai SR, Veeraraghavan S, Nikolakopolou A, Nicholson AG, Colby TV, Denton CP, Black CM, du Bois RM, Wells AU: CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Radiology 2004, 232:560–7.CrossRefPubMed
32.
Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A: Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993, 189:693–698.CrossRefPubMed
33.
Spencer H: Lung changes in progressive systemic sclerosis. In Pathology of the Lung. Oxford: Pergamon Press; 1977:741–46.
34.
D'Angelo WA, Fries JF, Masi AT, Shulman LE: Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428–40.CrossRefPubMed
35.
Beon M, Harley RA, Wessels A, Silver RM, Ludwicka-Bradley A: Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol 2004, 22:733–42.PubMed
36.
Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, Du Bois RM: The predictive value of appearances on thin section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993, 148:1076–82.CrossRefPubMed
37.
Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, du Bois RM: Fibrosing alveolitis in systemic sclerosis. Indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997, 40:1229–36.PubMed
38.
Warrick JH, Bhalla M, Schabel SI, Silver RM: High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991, 18:1520–8.PubMed
39.
Stuart RA, Littlewood AJ, Maddison PJ, Hall ND: Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995, 13:17–22.PubMed
40.
Sato S, Hasegawa M, Takehara K: Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001,27(2):140–6.CrossRefPubMed
41.
Baughman RP, Conrado CE: Diagnosis of lower respiratory tract infections. What we have and what would be nice. Chest 1998, 113:219S-223S.CrossRefPubMed
42.
Metadata
Title
Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis
Authors
Maria De Santis
Silvia Bosello
Giuseppe La Torre
Anna Capuano
Barbara Tolusso
Gabriella Pagliari
Riccardo Pistelli
Francesco Maria Danza
Angelo Zoli
Gianfranco Ferraccioli
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2005
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-6-96

Other articles of this Issue 1/2005

Respiratory Research 1/2005 Go to the issue

Research

Bacterial activity in cystic fibrosis lung infections

Research

Inhibition of breathing after surfactant depletion is achieved at a higher arterial PCO2 during ventilation with liquid than with gas

Research

A role for airway remodeling during respiratory syncytial virus infection

Research

Immune sensitization of equine bronchus: glutathione, IL-1β expression and tissue responsiveness

Review

Serum biomarkers in interstitial lung diseases

Research

Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits